Alembic Pharmaceuticals has announced a key leadership transition, confirming that Mr. Chirayu Amin has been appointed as the Executive Chairman of the company, effective April 1, 2026. Following a five-year mandate, this appointment follows his decision to relinquish his former role as the Chief Executive Officer. Mr. Amin continues to play a pivotal role in the company’s growth, strategy, and innovation, alongside his active involvement in various philanthropic and educational trusts.
Leadership Transition at the Helm
As of April 1, 2026, Alembic Pharmaceuticals has officially transitioned its leadership structure. Mr. Chirayu Amin, who previously served as the Chairman and CEO, has completed his tenure in the CEO role and has now been appointed as the Executive Chairman for a period of five years. This appointment was approved by the company’s shareholders during the 15th Annual General Meeting held on August 5, 2025.
Profile and Strategic Contribution
Mr. Chirayu Amin holds a bachelor’s degree in science from the Maharaja Sayajirao University of Baroda and an MBA from Seton Hall University, New Jersey. Under his stewardship, the company has achieved significant milestones and consistent growth. Beyond his corporate leadership, Mr. Amin is actively engaged in social welfare, serving as a trustee for several healthcare and educational institutions, including the Bhailal Amin General Hospital and the Uday Education Society.
Family and Governance
The company also confirmed the familial ties within its top management. Mr. Chirayu Amin is the father of Mr. Pranav Amin and Mr. Shaunak Amin, who both serve as Managing Directors of Alembic Pharmaceuticals, ensuring continuity and stability in the company’s long-term governance and operational strategy.
Source: BSE
